Equities

Clearbridge Health Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Clearbridge Health Ltd

Actions
  • Price (EUR)0.0005
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-50.00%
  • Beta1.6289
Data delayed at least 15 minutes, as of Feb 16 2026 07:20 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Clearbridge Health Limited is a Singapore-based investment holding company, which is engaged in integrated healthcare and medical services and developing solutions for early detection of cancer and critical illnesses. Its segments include Strategic investments, Healthcare systems, Medical clinics/centres, Corporate segment, and Investments. The Strategic investment segment is engaged in investments in identified early-stage biotechnology and information security companies. Healthcare systems segment is engaged in the provision of diagnostic services and provision of renal care services by partnering with medical device equipment manufacturers and hospitals. The Medical clinics/centres segment is engaged in the provision of general medical, dental, and clinical services. The Corporate segment involves corporate functions. The Investment segment invests in various entities in the global healthcare sector. It offers a comprehensive range of services, including medical centers and clinics.

  • Revenue in SGD (TTM)10.23m
  • Net income in SGD-2.75m
  • Incorporated2010
  • Employees115.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
1H3:SES since
announced
Transaction
value
Elpis Biopharmaceuticals Pte LtdAnnounced28 Apr 202528 Apr 2025Announced--330.00m
Data delayed at least 10 minutes, as of Feb 13 2026 09:04 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.